Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antinavikiniai vaistai - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antinavikiniai vaistai - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

boehringer ingelheim vetmedica gmbh (vokietija) - liofilizatas ir skiediklis - 2 ml atskiestos vakcinos yra:lawsonia intracellularis - 1 x 104,9 tcid 50 - 1 x 106,1 tcid 50. - trijų savaičių ir vyresnėms atjunkytoms kiaulėms aktyviai imunizuoti, norint sumažinti lawsonia intracellularis infekcijos sukeltų žarnyno pažeidimų ir su šia liga susijusį augimo netolygumą ir svorio netekimą.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

intervet international b.v. (nyderlandai) - liofilizatas ir skiediklis - kiekvienoje 2 ml atskiestos vakcinos dozėje yra: veikliosios medžiagos (liofilizato): inaktyvintų spah-08 padermės lawsonia intracellularis 5323 v1 - kiaulėms nuo 3 sav. amžiaus aktyviai imunizuoti, norint sumažinti lawsonia intracellularis infekcijos sukeltą viduriavimą, dienos svorio prieaugio nuostolius, žarnyno pažeidimus, bakterijų plitimą ir gaištamumą. imuniteto pradžia: 4 sav. po vakcinacijos. imuniteto trukmė: 21 sav. po vakcinacijos.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

intervet international b.v. (nyderlandai) - liofilizatas ir skiediklis - kiekvienoje 0,2 ml atskiestos vakcinos dozėje yra: veikliosios medžiagos (liofilizato): inaktyvintų spah-08 padermės lawsonia intracellularis 5323 v1. - kiaulėms nuo 3 sav. amžiaus aktyviai imunizuoti, norint sumažinti lawsonia intracellularis infekcijos sukeltą viduriavimą, dienos svorio prieaugio nuostolius, žarnyno pažeidimus, bakterijų plitimą ir gaištamumą. imuniteto pradžia: 4 sav. po vakcinacijos. imuniteto trukmė: 21 sav. po vakcinacijos.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bayer ag - sorafenibas - carcinoma, hepatocellular; carcinoma, renal cell - antinavikiniai vaistai - hepatocellular carcinomanexavar nurodomas gydymo hepatocellular karcinoma. inkstų ląstelių carcinomanexavar fluorouracilu ir gydomi pacientai, sergantys progresavusia inkstų ląstelių karcinoma, kurie nesugebėjo iki interferonu-alfa arba interleukinas-2 pagrindu terapija arba yra laikomi netinkami tokia terapija. diferencijuoto skydliaukės carcinomanexavar skiriamas pacientams, sergantiems progresuojančia, lokaliai išplitusio arba metastazavusio, diferencijuoti (papillary/follicular/hürthle ląstelių) skydliaukės karcinoma, ugniai atsparūs, kad radioaktyvaus jodo.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig  - pegfilgrastimas - neutropenija - immunostimulants, - neutropenija ir febrili neutropenija sergantiems suaugusiesiems pasireiškimo trukmės mažinimas pacientams, kurių onkologinės ligos (išskyrus lėtinį mieloidinę leukemiją ir mielodisplazinį sindromą).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antinavikiniai vaistai - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.